Hansoh Pharma (翰森制药) IPO: Competitive Landscape of HS-10296, the 3rd Gen EGFR TKI for Lung Cancer
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
866 Views
Hansoh Pharma IPO: Growth at the Cost of More Pre-IPO Dividends
Hansoh Pharmaceutical (HANSOH HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. According to press reports, Hansoh...
600 Views
ECM Weekly (4 May 2019) - Hansoh, Douyu, Eagle Hospitality, Mulsanne, Luckin
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
570 Views
Hansoh Pharma (翰森制药) IPO: New Numbers, Pre-IPO Dividend and Boyu Investment (Part 3)
Hansoh Pharma re-filed prospectus in April and is targeting a listing by summer. In our previous insight, we covered the company's major products...
771 Views
Last Week in GER Research: API/Sigma, M1, Eclipx/Mcmillan and Hansoh IPO
In this version of the GER weekly research wrap, we assess the bump prospects in the Australian Pharma Industries (API AU) / Sigma Healthcare (SIG...
443 Views